Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 285

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1

Open access
Naidoo, Jarushka, Schindler, Katja, Querfeld, Christiane, Busam, Klaus, Cunningham, Jane, Page, David B., Postow, Michael A., Weinstein, Alyona, Lucas, Anna Skripnik, Ciccolini, Kathryn T., Quigley, Elizabeth A., Lesokhin, Alexander M., Paik, Paul K., Chaft, Jamie E., Segal, Neil H., D'Angelo, Sandra P., Dickson, Mark A., Wolchok, Jedd D., Lacouture, Mario E.·2016·Cancer Immunology Research

Abstract

Monoclonal antibodies (mAb) targeting immune checkpoint pathways such as cytotoxic T-lymphocyte–associated protein 4 (CTLA-4) and programmed death 1 (PD-1) may confer durable disease control in several malignancies. In some patients, immune checkpoint mAbs cause cutaneous immune-related adverse events. Although the most commonly reported cutaneous toxicities are mild, a subset may persist despite therapy and can lead to severe or life-threatening toxicity. Autoimmune blistering disorders are not commonly associated with immune checkpoint mAb therapy. We report a case series of patients who developed bullous pemphigoid (BP), an autoimmune process classically attributed to pathologic autoantibody formation and complement deposition. Three patients were identified. Two patients developed BP while receiving the anti–PD-1 mAb nivolumab, and one while receiving the anti–PD-L1 mAb durvalumab. The clinicopathologic features of each patient and rash, and corresponding radiologic findings at the development of the rash and after its treatment, are described. Patients receiving an anti–PD-1/PD-L1 mAb may develop immune-related BP. This may be related to both T-cell– and B-cell–mediated responses. Referral to a dermatologist for accurate diagnosis and management is recommended. Cancer Immunol Res; 4(5); 383–9. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2326-6066.cir-15-0123

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 285

Metadata

Authors
Naidoo, J., Schindler, K., Querfeld, C., Busam, K., Cunningham, J., Page, D. B., Postow, M. A., Weinstein, A., Lucas, A. S., Ciccolini, K. T., Quigley, E. A., Lesokhin, A. M., Paik, P. K., Chaft, J. E., Segal, N. H., D'Angelo, S. P., Dickson, M. A., Wolchok, J. D., & Lacouture, M. E.
Venue
Cancer Immunology Research
Published
2016-05-01
Volume
4
Issue
5
Pages
383-389
ISSN
  • 2326-6066 (ISSN-L)
  • 2326-6074
OpenAlex
W2288531107
Cited by
285
References
21
FWCI
19.32
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. https://app.cochat.ai/papers/10.1158/2326-6066.cir-15-0123
The paper
Naidoo, J., Schindler, K., Querfeld, C., Busam, K., Cunningham, J., Page, D. B., Postow, M. A., Weinstein, A., Lucas, A. S., Ciccolini, K. T., Quigley, E. A., Lesokhin, A. M., Paik, P. K., Chaft, J. E., Segal, N. H., D'Angelo, S. P., Dickson, M. A., Wolchok, J. D., & Lacouture, M. E. (2016). Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-15-0123

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.